Galderma International

Galderma International is the international dermatology business now generally presented under the Galderma name. The company is headquartered in Zug, Switzerland, and operates as a specialist healthcare company rather than as a conventional generic-pharmaceutical brand. Its portfolio spans prescription dermatology medicines, injectable aesthetic products, and consumer-oriented skin-health products. This combination gives Galderma exposure to both medically supervised treatment and elective aesthetic care, while maintaining a common focus on skin, hair, and nails. The business originated in 1981 as a joint venture between Nestlé and L'Oréal. It was created to develop and commercialize dermatology products globally, bringing together Nestlé's healthcare interests and L'Oréal's dermatology and consumer-products capabilities. Over subsequent decades, Galderma built an international commercial and research network and developed a portfolio that included prescription treatments for acne, rosacea, psoriasis, atopic dermatitis, pigment disorders, and other dermatological conditions. It also became associated with professional aesthetic products, including injectable treatments based on botulinum toxin and hyaluronic acid, as well as devices and skincare used by physicians and aesthetic practitioners. A major ownership transition took place in 2019. Nestlé completed the sale of Galderma to a consortium led by EQT, with participation from other investors. The transaction separated Galderma from Nestlé's broader healthcare portfolio and established it as an independent dermatology company. Under private ownership, Galderma expanded its aesthetic and therapeutic activities, increased investment in innovation, and continued broadening its commercial presence across developed and emerging markets. Galderma has been associated with brands and products such as Cetaphil in consumer skin health; Restylane, Sculptra, and other injectable aesthetic offerings; Dysport in botulinum-toxin aesthetics and therapeutics; and prescription dermatology medicines including products developed or commercialized for acne and other inflammatory or pigment-related conditions. Product availability and ownership can vary by country, regulatory status, and commercial arrangement, so the global corporate portfolio should not be treated as identical in every market. In March 2024, Galderma completed an initial public offering on the SIX Swiss Exchange under the ticker GALD. The listing returned the company to public markets while preserving its identity as a focused dermatology platform. Its current strategic positioning combines three complementary areas: therapeutic dermatology, aesthetic injectables, and consumer skin health. Galderma's competitive environment includes pharmaceutical dermatology specialists, large diversified pharmaceutical companies, aesthetic-medicine manufacturers, medical-device businesses, and premium skincare companies. The company continues to rely on physician relationships, clinical evidence, regulatory approvals, brand recognition, and global distribution as central sources of competitive advantage.

Galderma was established in 1981 as a joint venture between Nestlé and L'Oréal. The venture was designed to concentrate on dermatology, an area requiring specialized clinical development, regulatory expertise, and relationships with dermatologists and other healthcare professionals. Its creation gave the partners a dedicated international platform for dermatological research and commercialization rather than treating skin health as only a small part of a broader pharmaceutical or cosmetics portfolio. During its development under Nestlé and L'Oréal ownership, Galderma expanded its presence across prescription dermatology, professional aesthetics, and skin health. Its prescription activities addressed conditions including acne, rosacea, psoriasis, atopic dermatitis, pigment disorders, and other diseases affecting the skin. The company also developed or commercialized products for medical aesthetics, including dermal fillers, botulinum-toxin treatments, and injectable products intended to improve skin quality or stimulate collagen formation. In consumer skin health, Cetaphil became one of the most recognizable names associated with the wider Galderma portfolio. The company’s evolution reflected the increasing overlap between medical dermatology and aesthetic medicine. Prescription dermatology depends on clinical trials, physician adoption, and regulatory approval, while aesthetic products depend on practitioner training, patient demand, product safety, and brand trust. Galderma built a business model around both markets, supported by global sales operations and specialized research and development. Its portfolio was not uniform across countries: individual products have different registrations, indications, distributors, and ownership arrangements. In 2019, Nestlé announced and completed the sale of Galderma to a consortium led by EQT. This transaction made Galderma an independent dermatology company and allowed its strategy to be managed separately from Nestlé’s broader food, nutrition, and healthcare interests. Following the transaction, Galderma continued investing in therapeutic dermatology and accelerated its emphasis on aesthetics and skin health. The company remained headquartered in Switzerland while operating internationally. Galderma subsequently expanded its commercial and innovation platform through product development, geographic growth, and selected portfolio activities. Its best-known commercial areas included the Restylane family of hyaluronic-acid fillers, Sculptra collagen-stimulating injectable treatment, Dysport botulinum-toxin products, prescription acne and inflammatory-dermatology treatments, and Cetaphil consumer skincare. The company also positioned aesthetics as a medically supervised specialty, emphasizing practitioner education and clinical support rather than treating injectables as ordinary cosmetics. In March 2024, Galderma completed an initial public offering on the SIX Swiss Exchange, trading under the symbol GALD. The listing created a public-market ownership structure and increased the company’s reporting obligations and visibility. Galderma’s present identity is that of a focused global dermatology platform with three principal pillars: therapeutic dermatology, aesthetic injectables, and consumer skin health. Its principal challenges include regulatory scrutiny, product safety, competition from pharmaceutical and aesthetic companies, changing consumer preferences, reimbursement conditions in prescription markets, and the need to maintain scientific credibility across both medical and elective-use categories.

1. 2024Initial public offering on SIX Swiss Exchange

   Galderma completes its IPO and begins trading on the SIX Swiss Exchange under the ticker GALD.

   Source
2. 2019Galderma becomes independent from Nestlé

   Nestlé sells Galderma to an investor consortium led by EQT, separating the dermatology company from Nestlé's corporate structure.

   Source
3. 1981Galderma is established

   Nestlé and L'Oréal establish Galderma as a joint venture focused on international dermatology research and commercialization.

   Source

A global specialist dermatology company combining prescription therapeutics, medical aesthetics, and consumer skin health. Its positioning is centered on science-led skin care and physician-supported treatment across the full dermatology lifecycle.

• CetaphilConsumer skin health

  Cetaphil is a consumer skin-health brand built around cleansers, moisturizers, sunscreens, and products for sensitive or dry skin. It is distributed through pharmacies, healthcare channels, and retail markets in many countries. The brand is positioned around gentle formulations and everyday skin-barrier care rather than prescription treatment. Product formulas, claims, and availability differ by market.

• RestylaneAesthetic injectables1996

  Restylane is a family of hyaluronic-acid injectable products used by qualified healthcare professionals for aesthetic indications such as facial volume enhancement, contouring, and wrinkle treatment. Different formulations are designed for different anatomical areas and treatment objectives. Regulatory indications and approved uses vary by jurisdiction, and the products are intended for professional administration rather than direct consumer use.

• SculptraAesthetic injectables

  Sculptra is an injectable aesthetic product based on poly-L-lactic acid. It is used by trained practitioners to stimulate gradual collagen production and address selected concerns involving facial volume and skin quality. Unlike an immediately volumizing filler, its results develop over time and may require a series of treatments. Approved indications and labeling differ across countries.

• DysportBotulinum-toxin therapeutics and aesthetics

  Dysport is a botulinum-toxin type A product used in approved therapeutic and aesthetic applications. Depending on jurisdiction, indications may include treatment of selected muscle-spasticity conditions and temporary improvement of facial expression lines. Administration requires appropriately trained medical professionals, and dosing units are product-specific rather than directly interchangeable with other botulinum-toxin brands.

• AkliefPrescription dermatology2019

  Aklief is a prescription topical retinoid product containing trifarotene. It is used for acne vulgaris in approved markets and was developed as a selective retinoic-acid receptor gamma agonist. As with other prescription retinoids, use is governed by local labeling and medical advice, including precautions concerning irritation and exposure during pregnancy.

• EpiduoPrescription dermatology

  Epiduo is a prescription acne treatment combining adapalene and benzoyl peroxide. It targets acne through complementary mechanisms and is marketed in several formulations and markets. The product's regulatory status, strength, naming, and availability depend on the country in which it is sold.

• DifferinPrescription and over-the-counter dermatology

  Differin is a dermatology brand associated primarily with adapalene-based acne treatment. Depending on the jurisdiction, formulations may be prescription-only or available without a prescription. The brand is used for acne management and is supported by the clinical history of topical retinoid therapy, subject to local labeling and professional guidance.

• 2024Public listing on SIX Swiss ExchangeStrategy

  After several years as an independently owned dermatology company, Galderma pursued access to public equity markets.

  What changed. Galderma completed an initial public offering and listed its shares on the SIX Swiss Exchange under the ticker GALD.

  Aftermath. The listing made Galderma a publicly traded specialist dermatology company and increased its public reporting and investor visibility.

  Source
• 2019Separation from Nestlé through sale to EQT-led consortiumM&A

  Nestlé decided to divest its dermatology business as part of a broader effort to focus its portfolio and simplify its ownership structure.

  What changed. Galderma was sold to an investor consortium led by EQT and continued as an independent dermatology company.

  Aftermath. The transaction gave Galderma independent ownership and enabled a strategy centered on therapeutic dermatology, aesthetics, and consumer skin health.

  Source

• 2024Galderma completes initial public offering on the SIX Swiss Exchange

  Galderma completed its initial public offering and began trading on the SIX Swiss Exchange under the symbol GALD, marking its return to public markets as an independent dermatology company.

  M&AOther
  Source
• 2019Nestlé agrees to sell Galderma to an investor consortium led by EQT

  Nestlé announced the sale of its dermatology business, Galderma, to an investor consortium led by EQT. The transaction separated Galderma from Nestlé and established it as an independent company.

  M&A
  Source

1. Galderma company information
2. Nestlé agrees to sell Galderma
3. Galderma news and investor information
4. Galderma leadership